In a report released yesterday, Danielle Antalffy from UBS upgraded Insulet to a Buy, with a price target of $400.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Danielle Antalffy has given her Buy rating due to a combination of factors that highlight Insulet’s strong growth potential and competitive positioning. The anticipated expansion in the Type 2 diabetes market is expected to significantly drive sales growth, with projections indicating a compound annual growth rate (CAGR) of 17% from 2025 to 2028. This growth is supported by key opinion leader checks and is expected to sustain momentum through the end of the decade.
Additionally, Insulet’s ability to maintain a competitive edge, despite potential market changes, is a crucial factor in the Buy rating. The company’s commitment to operating margin expansion and potential innovations in their product pipeline, such as AI integrations, further bolster this positive outlook. With these strategic advantages, Insulet is positioned as a durable growth stock in the small to mid-cap MedTech sector, offering tangible upside potential for investors over the next two years.
Antalffy covers the Healthcare sector, focusing on stocks such as Boston Scientific, Abbott Laboratories, and Edwards Lifesciences. According to TipRanks, Antalffy has an average return of 3.2% and a 51.96% success rate on recommended stocks.
In another report released on November 13, BTIG also maintained a Buy rating on the stock with a $370.00 price target.